Effects of opium inhalation on pulmonary volumes in smoking patients by Fadaii, Abbas et al.
 



















1Department of Pulmonology, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
2Department of Pediatrics, Semnan University of Medical Sciences, Semnan, Iran 
3Department of Pharmacology, Semnan University of Medical Sciences, Semnan, Iran 
 




       Historically, opium was used as a potent analgesic and to treat dyspnea and cough. It is documented that 
opium can increase exercise tolerance and relieve breathlessness. However, its overdose can suppress 
respiratory centers. The purpose of this study was to evaluate effects of opium on spirometric lung volumes. 
The study was done on two groups of patients referred to the lung clinic of Labbafi Nejad hospital. Group A 
was composed of 84 patients who were smokers and group B was made up of 40 patients who were smokers 
and opium addicts. Patients underwent spirometry and demographic questionnaires were collected. 
Significant differences were noted on lung volumes between two groups. Forced Vital Capacity (FVC) was 
56 ± 4.6 % in Group A and 72 ± 4.7 % in Group B (P < 0.001). Difference on Forced Expiratory Volume in 
one second (FEV1) was also statistically significant, 53 ± 6.6 % in Group A versus 69 ± 4.4 % in Group B (P 
< 0.001). In this study, lung volumes were considerably larger in patients who were opium addicts and 
smokers compared to patients who were only smokers. Further studies are warranted to confirm these results, 
and such confirmation may lead to better understanding about role of opioids in respiratory diseases. 
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INTRODUCTION 
     Some of Iranian population use opium to treat 
their physical or psychotic disorders. In Iranian 
traditional medicine, opium has been chiefly used 
for treatment of moderate to severe pains. Other 
indications include treatment of diarrhea, 
coughing and insomnia [1,2]. The most important 
side effects of this agent are dependence and 
addiction, which can lead to cognitive 
disturbances. Opium overdose can cause sever 
respiratory suppression, coma and death [3]. 
Opium can be used orally or inhalationally. Oral 
administration has slow onset, however, inhalation 
administration has rapid onset and shorter 
duration of action. There is an individual 
difference in amount of opium consumption, a 
study showed daily consumption from 0.75 gr to 
30 gr [4]. inhalation is the major root of 
administration of opium in Iran. The primary 
cause of chronic obstructive pulmonary disease 
(COPD) is cigarette smoking. As COPD 
progresses, dyspnea at rest develops and the 
ability to perform activities of daily living 
declines [5,6]. Evidence from several studies has 
supported usefulness of opium for alleviation of 
dyspnea [7-9]. However, these studies have not 
evaluated effects of opium on lung volumes. Our 
goal was to assess effects of opium inhalation on 
lung volumes. 
 
PATIENTS AND METHODS 
     Patients admitted to the lung clinic of Labbafi 
Nejad hospital, Tehran, Iran (2012-2013) with use 
of at least 20 pack/year of cigarette were included 
in the study. Exclusion criteria were history of 
cardiac and pulmonary diseases, exposure to 
chemical gases and hospitalization during 4 weeks 
prior to the study. Individuals who used opium 
orally were also excluded. Our study subjects 
were divided into two groups, A: smokers and B: 
smokers-addicts. All patients filled the required 
questionnaire. Clinical examinations and 
spirometry were done. Spirometric parameters 
including Forced Vital Capacity (FVC), Forced 
 




Expiratory Volume in one second (FEV1) and 
FEV1/FVC ratio were measured. The local ethical 
committee approved the study and informed 
consent letter was obtained from all participants. 
Data analysis 
Data are reported as mean ± SD or numbers. 
Kolmogrove-Smirnov and Levens tests showed 
normal distribution of data. Mean were compared 
by t-test. Differences at the level of P<0.05 were 
considered statistically significant. All analyses 
were performed using SPSS 16.0. 
 
RESULTS 
Characteristics of patients 
    Table 1 shows clinicopathological features of 
subjects. One hundred and twenty four patients 
were included in the study. Eighty-four patients in 
Group A, had history of smoking at least 20 
pack/year. In Group B, 40 patients had history of 
smoking at least 20 pack/year and also opium 
addiction for at least 10 years. All of the patients 
were male. Range of opium inhalation was from 3 
to 40 gr/day. There was no significant difference in 
medications between two groups. 
 
Table 1. Characteristics of Patients 
Characteristics Group A Group B 
Sex Male Male 
Age (years) 60 ± 2.4 61 ± 3.8 
Chief complaint Dyspnea Dyspnea 
Smoking yes yes 
Opium addiction no yes 
 
Table 2. Spirometric findings in Groups A and B. (Data 
are shown as mean ± SD) 
 
Spirometric findings 
     FVC, FEV1 and FEV1/FVC parameters were 
measured and compared within two groups (Table 
2). Mean of FVC was 56 ± 4.6 % in Group A and 
72 ± 4.7 % in Group B. This difference was 
statistically significant (P < 0.001). Difference in 
FEV1 value was also significant, 53 ± 6.6 % in 
Group A versus 69 ± 4.4 % in Group B (P < 
0.001). Mean of FEV1/FVC ratio was 68.4 ± 2.5 
% for Group A and 71.7 ± 3.7 % for group B (P > 
0.05). 
DISCUSSION 
     In the present study, we showed that patients 
using opium and cigarette had larger lung volumes 
compared to patients who only used cigarette. All 
individuals using opium are smokers, which is an 
important bias in investigations about opium and 
cigarette. Similar studies have not ruled out role of 
smoking, therefore they usually fail to gain a clear 
understanding about the effects of opium on lung 
volumes. Woodcock and colleagues showed that 
oral administration of 15mg hydrocodone could 
increase ability of 45 minutes walking up to 18% 
and relieved dyspnea up to 20% [10]. Light and 
colleagues discovered that 0.8 mg/kg morphine 
improved exercise tolerance up to 20% but caused 
a decrease in consciousness status [11]. Another 
study proved that inhalation of low dose morphine 
(less than 2mg/day) increased exercise time up to 
35% in patients with COPD [12]. Interestingly, A 
study on 54 opium addicts reported bronchitis; 
bronchiolitis and pulmonary fibrosis after more 
than 2 years follow up. In this study, cigarette 
smoking has not been excluded as an important 
factor to cause respiratory diseases [13]. Another 
study in Iran demonstrated that rate of 
cardiorespiratory diseases was higher in persons 
who had addiction to any substance. Importantly, 
the investigators considered cigarette as the most 
common substance of addiction [14]. An Indian 
investigation showed that opium addicts had 
smaller lung volumes and higher levels of hepatic 
enzymes compared to normal controls. In this 
study, root of opium administration and duration 
of addiction were not clarified [15]. Moreover, a 
study in Iran reported an increased rate of airway 
hyperresponsiveness in patients who were both 
opium and cigarette addicts [16]. Taken together, 
it seems that the exact role of inhalational opium 
in respiratory disease is elusive. Opioids may 
exert their effects either by induction of anxiolysis 
or by direct effect of respiratory centers located in 
the CNS. It seems the latter is the main 
mechanism causes alleviation of respiratory 
symptoms [17]. Peptides that are similar to 
opioids have been found in bronchial mucosa and 
can be new targets for pharmacotherapy [18]. 
Obviously, the risk of causing dependence is an 
important consideration in the therapeutic use of 
these drugs.  
 
Parameter Group A Group B P value 
FVC 56 ± 4.6 72 ± 4.7 0.001 
FEV1 53 ± 6.6 69 ± 4.4 0.001 
FEV1/FVC 68 ± 2.5 71 ± 3.7 0.07 
 




In the present study, patients in Group B had 
chronic use of opioids by inhalation and showed 
higher lung volume compared to smokers.  
 
CONCLUSION 
    Opioids may be helpful in patients with 
dyspnea. The untoward effects of opioids 
outweigh their benefits on respiratory disorders.  
Further investigations are required to provide 
deeper insight about the therapeutic consideration 
of opioids in respiratory diseases. 
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